Share Price and Basic Stock Data
Last Updated: January 10, 2026, 4:34 am
| PEG Ratio | -0.87 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bodal Chemicals Ltd operates in the dyes and pigments sector, with a current market capitalization of ₹654 Cr and a share price of ₹51.9. The company has shown fluctuating revenue trends over the past few quarters, with sales standing at ₹401.22 Cr in September 2022, declining to ₹320.73 Cr in December 2022 before recovering to ₹389.58 Cr in March 2023. For the subsequent quarters, sales have remained relatively stable, with ₹332.49 Cr in June 2023 and ₹330.00 Cr in September 2023, followed by a slight increase to ₹338.55 Cr in December 2023. The total sales for the trailing twelve months (TTM) reached ₹1,829 Cr, reflecting a gradual recovery compared to ₹1,574 Cr in March 2023. The annual sales data also indicates a recovery trend, with ₹1,395 Cr reported for March 2024 and an anticipated increase to ₹1,745 Cr by March 2025, suggesting a positive trajectory in revenue growth.
Profitability and Efficiency Metrics
Bodal Chemicals reported a net profit of ₹35 Cr, translating to a profit margin of 2.51% and a return on capital employed (ROCE) of 5.51%. Operating profit margins (OPM) have been relatively modest, recorded at 4.79%, which is below the typical sector average, indicating potential room for improvement in operational efficiency. The company reported operating profits of ₹32.09 Cr in September 2022, which fluctuated down to ₹22.21 Cr in June 2023. However, a rebound was noted in subsequent quarters, with operating profit rising to ₹34.46 Cr in June 2024. The interest coverage ratio (ICR) stood at 2.09x, suggesting that the company can cover its interest expenses comfortably, but this is lower compared to industry standards. Furthermore, the net profit has shown variability, with a decline in several quarters, reflecting the need for better cost management and revenue enhancement strategies.
Balance Sheet Strength and Financial Ratios
The balance sheet of Bodal Chemicals reflects a total borrowing of ₹866 Cr against reserves of ₹1,097 Cr, indicating a solid equity base relative to its debt load. The company’s debt-to-equity ratio of 0.81x suggests a moderate leverage level, which could be beneficial if managed effectively. The current ratio stands at 1.17x, indicating adequate short-term liquidity, while the quick ratio of 0.73x suggests that the company may face challenges in meeting short-term liabilities without selling inventory. The price-to-book value (P/BV) ratio is reported at 0.66x, indicating that the stock is trading below its book value, which may attract value-oriented investors. However, the return on equity (ROE) of 2.51% is lower than the industry average, highlighting potential underperformance in generating returns for shareholders. Overall, the financial metrics suggest a need for strategic improvements to enhance profitability and shareholder value.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bodal Chemicals indicates a strong promoter holding of 57.00%, which reflects a significant insider confidence in the company’s future. However, the foreign institutional investors (FIIs) hold only 0.29%, and domestic institutional investors (DIIs) have no stake, which may signal a lack of institutional interest. The public shareholding stands at 42.70%, with the number of shareholders increasing to 74,649, indicating a growing retail interest. This shift in shareholder composition could be viewed positively, as it suggests potential for increased liquidity and market activity. Nevertheless, the lack of institutional backing may raise concerns about the stock’s stability during market fluctuations. Additionally, the decline in FII participation from 2.42% in December 2022 to 0.29% in September 2025 could indicate caution among foreign investors towards the company’s performance.
Outlook, Risks, and Final Insight
Looking ahead, Bodal Chemicals faces both opportunities and challenges. The projected revenue growth to ₹1,745 Cr by March 2025 presents a positive outlook; however, the company must address its profitability issues and operational inefficiencies to capitalize on this potential. Risks include the high debt levels, which could impact financial stability, and the fluctuating profit margins that may deter investors. Additionally, the absence of institutional support raises concerns about the stock’s resilience to market volatility. Strengths lie in the solid promoter holding and the improving sales trend, indicating investor confidence and a potential recovery phase. To enhance its market position, Bodal Chemicals needs to focus on improving margins, optimizing costs, and attracting institutional investors. If successful, the company could emerge as a stronger player in the dyes and pigments sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Dynamic Industries Ltd | 33.9 Cr. | 112 | 190/68.5 | 18.6 | 162 | 0.89 % | 5.68 % | 3.39 % | 10.0 |
| Daikaffil Chemicals India Ltd | 42.0 Cr. | 70.0 | 263/68.5 | 13.2 | 0.00 % | 18.6 % | 18.6 % | 10.0 | |
| Amal Ltd | 781 Cr. | 632 | 1,148/462 | 20.2 | 91.7 | 0.16 % | 36.3 % | 35.0 % | 10.0 |
| Vidhi Specialty Food Ingredients Ltd | 1,673 Cr. | 335 | 570/272 | 34.8 | 62.2 | 1.49 % | 18.7 % | 14.9 % | 1.00 |
| Ushanti Colour Chem Ltd | 60.1 Cr. | 53.5 | 67.1/38.0 | 37.7 | 0.00 % | 0.98 % | 5.98 % | 10.0 | |
| Industry Average | 1,275.85 Cr | 286.58 | 90.40 | 186.93 | 0.41% | 11.00% | 9.10% | 8.13 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 401.22 | 320.73 | 389.58 | 332.49 | 330.00 | 338.55 | 393.59 | 421.96 | 428.63 | 443.47 | 450.87 | 454.20 | 480.45 |
| Expenses | 369.13 | 296.18 | 362.67 | 310.28 | 306.51 | 314.68 | 368.48 | 387.50 | 395.97 | 398.97 | 403.61 | 406.59 | 457.46 |
| Operating Profit | 32.09 | 24.55 | 26.91 | 22.21 | 23.49 | 23.87 | 25.11 | 34.46 | 32.66 | 44.50 | 47.26 | 47.61 | 22.99 |
| OPM % | 8.00% | 7.65% | 6.91% | 6.68% | 7.12% | 7.05% | 6.38% | 8.17% | 7.62% | 10.03% | 10.48% | 10.48% | 4.79% |
| Other Income | 1.69 | 2.22 | 3.89 | 8.78 | 5.93 | 4.65 | 5.45 | 2.46 | 5.07 | 0.65 | 2.35 | 4.05 | 19.90 |
| Interest | 7.26 | 10.11 | 11.58 | 13.15 | 13.42 | 12.09 | 15.60 | 21.33 | 19.54 | 19.71 | 21.00 | 21.63 | 19.92 |
| Depreciation | 12.19 | 13.92 | 14.65 | 14.65 | 14.31 | 14.52 | 17.01 | 17.03 | 17.20 | 17.26 | 17.01 | 17.51 | 17.42 |
| Profit before tax | 14.33 | 2.74 | 4.57 | 3.19 | 1.69 | 1.91 | -2.05 | -1.44 | 0.99 | 8.18 | 11.60 | 12.52 | 5.55 |
| Tax % | 28.33% | 11.31% | 38.51% | 30.72% | 26.04% | 49.21% | -200.00% | -18.75% | 124.24% | 33.74% | -25.09% | 23.88% | -7.93% |
| Net Profit | 10.27 | 2.43 | 2.81 | 2.21 | 1.24 | 0.98 | 2.04 | -1.18 | -0.24 | 5.42 | 14.50 | 9.53 | 5.99 |
| EPS in Rs | 0.84 | 0.19 | 0.22 | 0.18 | 0.10 | 0.08 | 0.16 | -0.09 | -0.02 | 0.43 | 1.15 | 0.76 | 0.48 |
Last Updated: January 2, 2026, 5:01 am
Below is a detailed analysis of the quarterly data for Bodal Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 480.45 Cr.. The value appears strong and on an upward trend. It has increased from 454.20 Cr. (Jun 2025) to 480.45 Cr., marking an increase of 26.25 Cr..
- For Expenses, as of Sep 2025, the value is 457.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 406.59 Cr. (Jun 2025) to 457.46 Cr., marking an increase of 50.87 Cr..
- For Operating Profit, as of Sep 2025, the value is 22.99 Cr.. The value appears to be declining and may need further review. It has decreased from 47.61 Cr. (Jun 2025) to 22.99 Cr., marking a decrease of 24.62 Cr..
- For OPM %, as of Sep 2025, the value is 4.79%. The value appears to be declining and may need further review. It has decreased from 10.48% (Jun 2025) to 4.79%, marking a decrease of 5.69%.
- For Other Income, as of Sep 2025, the value is 19.90 Cr.. The value appears strong and on an upward trend. It has increased from 4.05 Cr. (Jun 2025) to 19.90 Cr., marking an increase of 15.85 Cr..
- For Interest, as of Sep 2025, the value is 19.92 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 21.63 Cr. (Jun 2025) to 19.92 Cr., marking a decrease of 1.71 Cr..
- For Depreciation, as of Sep 2025, the value is 17.42 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 17.51 Cr. (Jun 2025) to 17.42 Cr., marking a decrease of 0.09 Cr..
- For Profit before tax, as of Sep 2025, the value is 5.55 Cr.. The value appears to be declining and may need further review. It has decreased from 12.52 Cr. (Jun 2025) to 5.55 Cr., marking a decrease of 6.97 Cr..
- For Tax %, as of Sep 2025, the value is -7.93%. The value appears to be improving (decreasing) as expected. It has decreased from 23.88% (Jun 2025) to -7.93%, marking a decrease of 31.81%.
- For Net Profit, as of Sep 2025, the value is 5.99 Cr.. The value appears to be declining and may need further review. It has decreased from 9.53 Cr. (Jun 2025) to 5.99 Cr., marking a decrease of 3.54 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.48. The value appears to be declining and may need further review. It has decreased from 0.76 (Jun 2025) to 0.48, marking a decrease of 0.28.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:33 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 960 | 1,043 | 908 | 1,233 | 1,142 | 1,424 | 1,375 | 1,226 | 2,055 | 1,574 | 1,395 | 1,745 | 1,829 |
| Expenses | 770 | 859 | 758 | 1,007 | 946 | 1,187 | 1,237 | 1,140 | 1,835 | 1,441 | 1,284 | 1,578 | 1,667 |
| Operating Profit | 189 | 184 | 150 | 226 | 196 | 236 | 138 | 87 | 220 | 133 | 111 | 167 | 162 |
| OPM % | 20% | 18% | 16% | 18% | 17% | 17% | 10% | 7% | 11% | 8% | 8% | 10% | 9% |
| Other Income | -70 | 5 | 19 | 15 | 8 | 13 | 10 | 16 | -2 | 12 | 9 | 2 | 27 |
| Interest | 47 | 27 | 12 | 9 | 5 | 9 | 19 | 17 | 29 | 41 | 54 | 82 | 82 |
| Depreciation | 25 | 22 | 26 | 29 | 12 | 21 | 28 | 30 | 47 | 53 | 60 | 69 | 69 |
| Profit before tax | 47 | 139 | 131 | 204 | 186 | 219 | 101 | 55 | 142 | 51 | 5 | 19 | 38 |
| Tax % | 35% | 34% | 34% | 35% | 33% | 35% | 15% | 28% | 31% | 25% | -37% | 4% | |
| Net Profit | 30 | 92 | 86 | 133 | 122 | 141 | 86 | 40 | 99 | 38 | 6 | 18 | 35 |
| EPS in Rs | 2.76 | 8.41 | 7.88 | 12.18 | 10.03 | 11.72 | 7.12 | 3.43 | 8.51 | 3.03 | 0.51 | 1.47 | 2.82 |
| Dividend Payout % | 0% | 0% | 8% | 7% | 8% | 7% | 11% | 23% | 9% | 3% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 206.67% | -6.52% | 54.65% | -8.27% | 15.57% | -39.01% | -53.49% | 147.50% | -61.62% | -84.21% | 200.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -213.19% | 61.17% | -62.92% | 23.84% | -54.58% | -14.48% | 200.99% | -209.12% | -22.59% | 284.21% |
Bodal Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | -5% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -14% |
| 5 Years: | -26% |
| 3 Years: | -45% |
| TTM: | 875% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -2% |
| 3 Years: | -13% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 4% |
| 3 Years: | 2% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 1:10 am
Balance Sheet
Last Updated: December 4, 2025, 1:03 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 24 | 24 | 24 | 24 | 24 | 25 | 25 | 25 | 25 |
| Reserves | 43 | 135 | 213 | 341 | 673 | 805 | 907 | 957 | 1,028 | 1,053 | 1,057 | 1,080 | 1,097 |
| Borrowings | 397 | 234 | 143 | 151 | 181 | 171 | 257 | 454 | 676 | 760 | 904 | 911 | 866 |
| Other Liabilities | 131 | 144 | 132 | 193 | 194 | 290 | 267 | 314 | 385 | 283 | 294 | 324 | 325 |
| Total Liabilities | 593 | 534 | 510 | 707 | 1,072 | 1,290 | 1,455 | 1,749 | 2,113 | 2,120 | 2,281 | 2,339 | 2,313 |
| Fixed Assets | 168 | 190 | 192 | 222 | 437 | 609 | 656 | 804 | 817 | 967 | 1,314 | 1,301 | 1,278 |
| CWIP | 9 | 3 | 0 | 9 | 19 | 26 | 7 | 14 | 70 | 193 | 68 | 61 | 61 |
| Investments | 1 | 2 | 2 | 17 | 17 | 6 | 3 | 6 | 0 | 0 | 13 | 0 | 0 |
| Other Assets | 415 | 339 | 316 | 459 | 599 | 650 | 789 | 924 | 1,227 | 960 | 886 | 977 | 973 |
| Total Assets | 593 | 534 | 510 | 707 | 1,072 | 1,290 | 1,455 | 1,749 | 2,113 | 2,120 | 2,281 | 2,339 | 2,313 |
Below is a detailed analysis of the balance sheet data for Bodal Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,097.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,080.00 Cr. (Mar 2025) to 1,097.00 Cr., marking an increase of 17.00 Cr..
- For Borrowings, as of Sep 2025, the value is 866.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 911.00 Cr. (Mar 2025) to 866.00 Cr., marking a decrease of 45.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 325.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 324.00 Cr. (Mar 2025) to 325.00 Cr., marking an increase of 1.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,313.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,339.00 Cr. (Mar 2025) to 2,313.00 Cr., marking a decrease of 26.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,278.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,301.00 Cr. (Mar 2025) to 1,278.00 Cr., marking a decrease of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 61.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 61.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 973.00 Cr.. The value appears to be declining and may need further review. It has decreased from 977.00 Cr. (Mar 2025) to 973.00 Cr., marking a decrease of 4.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,313.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,339.00 Cr. (Mar 2025) to 2,313.00 Cr., marking a decrease of 26.00 Cr..
Notably, the Reserves (1,097.00 Cr.) exceed the Borrowings (866.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -208.00 | -50.00 | 7.00 | 75.00 | 15.00 | 65.00 | -119.00 | -367.00 | -456.00 | -627.00 | -793.00 | -744.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 86 | 69 | 67 | 56 | 91 | 85 | 121 | 139 | 105 | 97 | 100 | 83 |
| Inventory Days | 72 | 43 | 57 | 60 | 59 | 86 | 91 | 141 | 141 | 119 | 139 | 139 |
| Days Payable | 66 | 62 | 67 | 73 | 79 | 91 | 87 | 102 | 81 | 72 | 102 | 97 |
| Cash Conversion Cycle | 92 | 50 | 58 | 43 | 71 | 79 | 124 | 178 | 165 | 144 | 137 | 125 |
| Working Capital Days | 41 | 23 | 18 | 21 | 58 | 50 | 65 | 73 | 55 | 49 | 19 | 20 |
| ROCE % | 39% | 39% | 35% | 46% | 27% | 24% | 11% | 5% | 12% | 5% | 3% | 6% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 1.47 | 0.51 | 3.03 | 8.79 | 3.25 |
| Diluted EPS (Rs.) | 1.47 | 0.51 | 3.03 | 8.79 | 3.24 |
| Cash EPS (Rs.) | 6.91 | 5.32 | 7.25 | 11.86 | 5.74 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 87.72 | 86.04 | 85.79 | 85.92 | 80.10 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 87.72 | 86.04 | 85.79 | 85.92 | 80.10 |
| Revenue From Operations / Share (Rs.) | 138.55 | 110.87 | 125.32 | 167.42 | 100.26 |
| PBDIT / Share (Rs.) | 13.55 | 9.50 | 11.54 | 19.34 | 8.38 |
| PBIT / Share (Rs.) | 8.11 | 4.69 | 7.31 | 15.54 | 5.89 |
| PBT / Share (Rs.) | 1.53 | 0.37 | 4.05 | 11.60 | 4.53 |
| Net Profit / Share (Rs.) | 1.47 | 0.51 | 3.03 | 8.06 | 3.25 |
| NP After MI And SOA / Share (Rs.) | 1.47 | 0.51 | 3.03 | 8.79 | 3.43 |
| PBDIT Margin (%) | 9.77 | 8.56 | 9.20 | 11.55 | 8.35 |
| PBIT Margin (%) | 5.85 | 4.22 | 5.83 | 9.28 | 5.87 |
| PBT Margin (%) | 1.10 | 0.33 | 3.22 | 6.92 | 4.51 |
| Net Profit Margin (%) | 1.06 | 0.46 | 2.41 | 4.81 | 3.24 |
| NP After MI And SOA Margin (%) | 1.06 | 0.46 | 2.41 | 5.25 | 3.42 |
| Return on Networth / Equity (%) | 1.67 | 0.59 | 3.52 | 10.19 | 4.30 |
| Return on Capital Employeed (%) | 6.43 | 3.70 | 6.12 | 14.44 | 6.33 |
| Return On Assets (%) | 0.78 | 0.28 | 1.79 | 5.07 | 2.40 |
| Long Term Debt / Equity (X) | 0.36 | 0.40 | 0.33 | 0.20 | 0.10 |
| Total Debt / Equity (X) | 0.81 | 0.82 | 0.70 | 0.54 | 0.35 |
| Asset Turnover Ratio (%) | 0.75 | 0.63 | 0.74 | 0.96 | 0.71 |
| Current Ratio (X) | 1.17 | 1.17 | 1.37 | 1.41 | 1.43 |
| Quick Ratio (X) | 0.73 | 0.78 | 0.89 | 0.85 | 0.92 |
| Inventory Turnover Ratio (X) | 5.77 | 4.98 | 2.24 | 3.10 | 3.25 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 19.44 | 25.79 | 9.10 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 1.87 | 10.76 | 6.35 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 80.56 | 74.21 | 90.90 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 98.13 | 89.24 | 93.65 | 0.00 |
| Interest Coverage Ratio (X) | 2.09 | 2.20 | 3.53 | 8.04 | 6.16 |
| Interest Coverage Ratio (Post Tax) (X) | 1.24 | 1.12 | 1.93 | 4.98 | 3.39 |
| Enterprise Value (Cr.) | 1607.20 | 1786.11 | 1466.28 | 1791.70 | 1436.56 |
| EV / Net Operating Revenue (X) | 0.92 | 1.28 | 0.93 | 0.87 | 1.17 |
| EV / EBITDA (X) | 9.42 | 14.95 | 10.12 | 7.56 | 14.01 |
| MarketCap / Net Operating Revenue (X) | 0.42 | 0.66 | 0.46 | 0.60 | 0.89 |
| Retention Ratios (%) | 0.00 | 80.55 | 74.20 | 90.89 | 0.00 |
| Price / BV (X) | 0.66 | 0.85 | 0.67 | 1.17 | 1.13 |
| Price / Net Operating Revenue (X) | 0.42 | 0.66 | 0.46 | 0.60 | 0.89 |
| EarningsYield | 0.02 | 0.01 | 0.05 | 0.08 | 0.03 |
After reviewing the key financial ratios for Bodal Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 5. It has increased from 0.51 (Mar 24) to 1.47, marking an increase of 0.96.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 5. It has increased from 0.51 (Mar 24) to 1.47, marking an increase of 0.96.
- For Cash EPS (Rs.), as of Mar 25, the value is 6.91. This value is within the healthy range. It has increased from 5.32 (Mar 24) to 6.91, marking an increase of 1.59.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 87.72. It has increased from 86.04 (Mar 24) to 87.72, marking an increase of 1.68.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 87.72. It has increased from 86.04 (Mar 24) to 87.72, marking an increase of 1.68.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 138.55. It has increased from 110.87 (Mar 24) to 138.55, marking an increase of 27.68.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.55. This value is within the healthy range. It has increased from 9.50 (Mar 24) to 13.55, marking an increase of 4.05.
- For PBIT / Share (Rs.), as of Mar 25, the value is 8.11. This value is within the healthy range. It has increased from 4.69 (Mar 24) to 8.11, marking an increase of 3.42.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 0.37 (Mar 24) to 1.53, marking an increase of 1.16.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 2. It has increased from 0.51 (Mar 24) to 1.47, marking an increase of 0.96.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 2. It has increased from 0.51 (Mar 24) to 1.47, marking an increase of 0.96.
- For PBDIT Margin (%), as of Mar 25, the value is 9.77. This value is below the healthy minimum of 10. It has increased from 8.56 (Mar 24) to 9.77, marking an increase of 1.21.
- For PBIT Margin (%), as of Mar 25, the value is 5.85. This value is below the healthy minimum of 10. It has increased from 4.22 (Mar 24) to 5.85, marking an increase of 1.63.
- For PBT Margin (%), as of Mar 25, the value is 1.10. This value is below the healthy minimum of 10. It has increased from 0.33 (Mar 24) to 1.10, marking an increase of 0.77.
- For Net Profit Margin (%), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 5. It has increased from 0.46 (Mar 24) to 1.06, marking an increase of 0.60.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 8. It has increased from 0.46 (Mar 24) to 1.06, marking an increase of 0.60.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.67. This value is below the healthy minimum of 15. It has increased from 0.59 (Mar 24) to 1.67, marking an increase of 1.08.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.43. This value is below the healthy minimum of 10. It has increased from 3.70 (Mar 24) to 6.43, marking an increase of 2.73.
- For Return On Assets (%), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 5. It has increased from 0.28 (Mar 24) to 0.78, marking an increase of 0.50.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.36. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.36, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.81. This value is within the healthy range. It has decreased from 0.82 (Mar 24) to 0.81, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.75. It has increased from 0.63 (Mar 24) to 0.75, marking an increase of 0.12.
- For Current Ratio (X), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 24) which recorded 1.17.
- For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.73, marking a decrease of 0.05.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.77. This value is within the healthy range. It has increased from 4.98 (Mar 24) to 5.77, marking an increase of 0.79.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 19.44 (Mar 24) to 0.00, marking a decrease of 19.44.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 1.87 (Mar 24) to 0.00, marking a decrease of 1.87.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 80.56 (Mar 24) to 0.00, marking a decrease of 80.56.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 98.13 (Mar 24) to 0.00, marking a decrease of 98.13.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.09. This value is below the healthy minimum of 3. It has decreased from 2.20 (Mar 24) to 2.09, marking a decrease of 0.11.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.24. This value is below the healthy minimum of 3. It has increased from 1.12 (Mar 24) to 1.24, marking an increase of 0.12.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,607.20. It has decreased from 1,786.11 (Mar 24) to 1,607.20, marking a decrease of 178.91.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.28 (Mar 24) to 0.92, marking a decrease of 0.36.
- For EV / EBITDA (X), as of Mar 25, the value is 9.42. This value is within the healthy range. It has decreased from 14.95 (Mar 24) to 9.42, marking a decrease of 5.53.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.42. This value is below the healthy minimum of 1. It has decreased from 0.66 (Mar 24) to 0.42, marking a decrease of 0.24.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 80.55 (Mar 24) to 0.00, marking a decrease of 80.55.
- For Price / BV (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 1. It has decreased from 0.85 (Mar 24) to 0.66, marking a decrease of 0.19.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.42. This value is below the healthy minimum of 1. It has decreased from 0.66 (Mar 24) to 0.42, marking a decrease of 0.24.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bodal Chemicals Ltd:
- Net Profit Margin: 1.06%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.43% (Industry Average ROCE: 11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.67% (Industry Average ROE: 9.1%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.24
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 17.2 (Industry average Stock P/E: 90.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.81
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.06%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Dyes & Pigments | Bodal Corporate House, Beside Maple Green Residency, Ahmedabad Gujarat 380059 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Suresh J Patel | Chairman & Managing Director |
| Mr. Bhavin S Patel | Executive Director |
| Mr. Ankit S Patel | Executive Director |
| Mr. Rohit Maloo | Independent Director |
| Mr. Nalin Kumar | Independent Director |
| Mrs. Neha Huddar | Independent Director |
| Mr. Mayank K Mehta | Independent Director |
| Mr. Rajarshi Gosh | Director |
FAQ
What is the intrinsic value of Bodal Chemicals Ltd?
Bodal Chemicals Ltd's intrinsic value (as of 11 January 2026) is ₹31.39 which is 36.84% lower the current market price of ₹49.70, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹626 Cr. market cap, FY2025-2026 high/low of ₹81.5/49.5, reserves of ₹1,097 Cr, and liabilities of ₹2,313 Cr.
What is the Market Cap of Bodal Chemicals Ltd?
The Market Cap of Bodal Chemicals Ltd is 626 Cr..
What is the current Stock Price of Bodal Chemicals Ltd as on 11 January 2026?
The current stock price of Bodal Chemicals Ltd as on 11 January 2026 is ₹49.7.
What is the High / Low of Bodal Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bodal Chemicals Ltd stocks is ₹81.5/49.5.
What is the Stock P/E of Bodal Chemicals Ltd?
The Stock P/E of Bodal Chemicals Ltd is 17.2.
What is the Book Value of Bodal Chemicals Ltd?
The Book Value of Bodal Chemicals Ltd is 89.1.
What is the Dividend Yield of Bodal Chemicals Ltd?
The Dividend Yield of Bodal Chemicals Ltd is 0.00 %.
What is the ROCE of Bodal Chemicals Ltd?
The ROCE of Bodal Chemicals Ltd is 5.51 %.
What is the ROE of Bodal Chemicals Ltd?
The ROE of Bodal Chemicals Ltd is 2.51 %.
What is the Face Value of Bodal Chemicals Ltd?
The Face Value of Bodal Chemicals Ltd is 2.00.